SAN ANTONIO, Texas, June 30, 2020 /CNW/ - Nerium Biotechnology, Inc. (the "Company"), announces today that its board of directors (the "Board") has called its annual general meeting (the "Meeting") of holders of common shares of the Company (the "Shareholders") to be held at The National Club, 303 Bay Street, Toronto, Ontario M5H 2R1 on Thursday, August 27, 2020 at 10:00 a.m. (Toronto time). The Board has fixed Monday, July 27, 2020 as the record date for the Meeting.
A notice of meeting, management information circular and form of proxy (or voting instruction form for non-registered Shareholders) in connection with the Meeting will be mailed to Shareholders prior to the Meeting. and, following mailing, will be filed on the Company's profile on SEDAR.
About Nerium Biotechnology, Inc.
Nerium Biotechnology, Inc. is a biotechnology company involved in the research, product development, manufacture and marketing of Nerium oleander-based products. The Company's shares are not listed on any stock exchange or quotation system.
Forward Looking Statements: Statements made in this press release that relate to future plans, expectations, events or performances are forward looking statements. Forward-looking statements are not based on historic facts, but rather on current expectations regarding future events. They are based on information available to management and/or assumptions management believes are reasonable. Many factors could cause future events and outcomes to differ materially from those discussed in the forward-looking statements. Although the forward-looking statements are based on what management believes are reasonable assumptions, the Company cannot assure Shareholders that actual results will be consistent with these forward-looking statements. The forward-looking statements in this press release are made as of the date hereof and, except as required by applicable securities laws, the Company does not assume any obligation to update or revise such forward-looking statements. More information about the Company is available in its disclosure documents, all of which are available on the Company's issuer profile on SEDAR at www.sedar.com.
SOURCE Nerium Biotechnology, Inc.